Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Treatment options for patients with heavily pretreated relapsed and/or refractory multiple myeloma remain limited. We evaluated a novel therapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label, multicenter, phase 1, dose-escalation study. Patients who rel...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Shah, Jatin J., Stadtmauer, Edward A., Abonour, Rafat, Cohen, Adam D., Bensinger, William I., Gasparetto, Cristina, Kaufman, Jonathan L., Lentzsch, Suzanne, Vogl, Dan T., Gomes, Christina L., Pascucci, Natalia, Smith, David D., Orlowski, Robert Z., Durie, Brian G. M.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4643003/
https://ncbi.nlm.nih.gov/pubmed/26384354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-643320
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg